Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News: $SRPT These 3 Value Stocks Are Absurdly Cheap Right Now
Value stocks are almost always a worthwhile addition to a well-rounded portfolio. Under-the-radar stocks trading at discounted valuations, after all, generally perform well in any type of market. That said, it's not necessarily easy to differentiate between a stock that's truly undervalued, an...
Read the whole news SRPT - These 3 Value Stocks Are Absurdly Cheap Right Now
News: $SRPT Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
-- Improvements on functional measures seen in all three participants -- -- Significant reduction in creatine kinase maintained over nine months -- -- Results follow positive and robust expression and biomarker data presented earlier in 2019 -- CAMBRIDGE, Mass., Oct. 04, 2019 (GLOBE ...
Find out more SRPT - Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
Yes Yoy Yoy.
Duuuude.....get lost
There are far better ones with upcoming catalysts such as TYME, ZYNE, FOLD.
Not invested in Srpt but thanks for asking!
How is SRPT working out for ya?
Wtf are you doing on ihub!? Yiu got kicked off for your fake news
Moved up a bit too much today?
Near term, is anyone seeing any catalyst that will take this higher?
Was there a 930k sell off . Who was that ?
It is good to see much needed funding come to a company doing this work, but they need to improve on efficiencies. There is a bit of sudden wealth phenomenon going on behind the curtain. Appropriation has gotten more lax.
Surprise this page is not active as others .
Great time to have this stock. Their product release as well as the demand with the company is growing at a rapid pace and the 48% increase today is a reflection of that.
SRPT leading indicators predicted the upward trend at the beginning of June. #BluSignals
https://www.blusignalsystems.com/srpt-leading-indicators/
HFS!!! I am glad I kept half of my holdings here when my initial investment doubled.
WONDER COMPANY $SRPT
Sarepta Therapeutics (SRPT)
67.02 ? 1.37 (2.09%)
Volume: 1,825,449 @ 5:50:10 PM EST ET
Bid Ask Day's Range
66.86 67.01 65.1 - 67.74
SRPT Detailed Quote
You probably did not see AMZN’s data in recent years.
Can anyone help me to understand how a company with a P/E of -28 can have a Market Cap close to $4 Billion?
could be buyout thing $srpt
Major resistance level here, will it break through?
Sarepta Therapeutics (SRPT)
40.23 ? 0.96 (2.44%)
Volume: 1,796,415 @ 2:01:33 PM EDT ET
Bid Ask Day's Range
40.2 40.22 38.64 - 40.66
SRPT Detailed Quote
No prob with the PM...I saw the offering here and the increase. Don't think will reenter, though
I nibbled just a little yesterday. By the way, I can't PM anymore, which is why I never responded.
are you in this to....we bought last year on dip. 29 change and sold in the mid 50's.. I have a friend who has been in this since the beginning and has not sold one share.
Seems like a limited market but a good drug if it helps people
What's the price to buy back?
Nice dip...loaded up a bunch more shares at $41. Watching for around $55 next week, might have a nice gap and run tomorrow.
You were correct! took profit at 43.5x
Sarepta Therapeutics (SRPT)
34.36 ? 0.3 (0.88%)
Volume: 962,283 @ 4:32:31 PM ET
Bid Ask Day's Range
34.03 34.46 33.61 - 34.58
SRPT Detailed Quote
Huge announcement of new CEO + earnings coming 7/19. Rumors of their new drug also helps in reducing migraines? A screaming buy!!
This one has been a downer for me! I finally was able to close out a Put I had sold. Around $35.00 I sold my other shares. So far it looks like it was a very smart move. No idea where this is headed? Good luck. JMO
SRPT News: Quarterly Report (10-q) 05/04/2017 04:05:07 PM
SRPT News: Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 05/01/2017 05:30:00 PM
SRPT News: Current Report Filing (8-k) 04/27/2017 05:08:41 PM
SRPT News: Additional Proxy Soliciting Materials (definitive) (defa14a) 04/27/2017 05:05:40 PM
SRPT News: Proxy Statement (definitive) (def 14a) 04/27/2017 05:03:08 PM
Sarepta Therapeutics (SRPT)
32.27 ? 0.0 (0.00%)
Volume: 0 @- ET
Bid Ask Day's Range
32.12 33.67 - - -
SRPT Detailed Quote
I sure hope this pops. I am taking a royal beating on this stock over the past month or so.....royal...
SRPT is about to pop. Watched the last 15 minutes on level 2 and tomorrow looks interesting to say the least
Sarepta Therapeutics (SRPT)
38.86 ? 4.14 (11.92%)
Volume: 3,608,317 @ 9:56:15 AM ET
Bid Ask Day's Range
38.84 38.88 37.03 - 39.34
SRPT Detailed Quote
SRPT News: Current Report Filing (8-k) 04/27/2017 05:08:41 PM
SRPT News: Additional Proxy Soliciting Materials (definitive) (defa14a) 04/27/2017 05:05:40 PM
SRPT News: Proxy Statement (definitive) (def 14a) 04/27/2017 05:03:08 PM
SRPT News: Current Report Filing (8-k) 04/27/2017 04:33:54 PM
SRPT News: Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments 04/27/2017 04:01:00 PM
News News Alert: Current Report Filing (8-k) 04/27/2017 05:08:41 PM
Followers
|
127
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3058
|
Created
|
11/16/05
|
Type
|
Free
|
Moderators |
http://www.sareptatherapeutics.com/
http://www.antivirals.com/
http://finance.yahoo.com/q/h?s=AVII
http://www.form4oracle.com/company?cik=0000873303&ticker=avii
http://www.secform4.com/insider-trading/873303.htm
Sarepta Therapeutics - formerly AVI BioPharma - remains focused on developing first-in-class, RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. Sarepta's unique technology has yielded a diverse pipeline of RNA-based therapeutics that include our lead clinical candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy, a debilitating and life-threatening genetic disorder, as well as potential treatments for some of the world's most lethal infectious diseases.
Our exceptional science- and commercialization-focused team is committed to realizing our vision of becoming a leading, independent biotechnology company dedicated to translating our RNA-based science into transformational therapeutics and, most importantly, bringing these novel therapeutics to patients who have no other options.
AVI BioPharma, Inc., a biopharmaceutical company, develops therapeutic products principally based on NEUGENE antisense technology. It offers various drugs for the treatment of cardiovascular diseases, infectious diseases, cancer, and polycystic kidney diseases, as well as for regulating drug metabolism. The company has collaboration agreement with Chiron Corporation for research, development, and commercialization of antisense therapeutics against hepatitis C virus; Cook Group Incorporated for the development and commercialization of products for vascular diseases; and Ercole Biotech, Inc. to identify and develop drugs that direct the splicing of messenger RNA to treat a range of genetic and acquired diseases. AVI BioPharma was founded in 1980 and is based in Portland, Oregon.
Form Type | Received | Period Ending | Size | Report |
---|---|---|---|---|
PRE 14A | May 16, 2016 | Jun 27, 2016 | 2.7 MB | PDF RTF HTML XLS |
SC 13G | May 6, 2016 | 14.4 KB | PDF RTF HTML XLS | |
8-K | May 5, 2016 | May 5, 2016 | 72.4 KB | PDF RTF HTML XLS |
10-Q | May 5, 2016 | Mar 31, 2016 | 5.0 MB | PDF RTF HTML XLS |
10-K/A | Apr 29, 2016 | Dec 31, 2015 | 2.0 MB | PDF RTF HTML XLS |
4 | Apr 22, 2016 | Apr 20, 2016 | 5.0 KB | PDF RTF HTML XLS |
4 | Mar 17, 2016 | Mar 14, 2016 | 7.4 KB | PDF RTF HTML XLS |
4 | Mar 17, 2016 | Mar 14, 2016 | 5.2 KB | PDF RTF HTML XLS |
4 | Mar 17, 2016 | Mar 14, 2016 | 4.7 KB | PDF RTF HTML XLS |
8-K | Mar 8, 2016 | Mar 7, 2016 | 30.8 KB | PDF RTF HTML XLS |
Phone and email address..................Lead investigator in the DMD trial.....London College of Medicine
http://www1.imperial.ac.uk/medicine/people/f.muntoni/
DISCLAIMER:
•The Board Monitor and The Board Assistants herewith, Are not licensed brokers and assume NO Responsibility for the Actions,
Investment decisions, and or Messages Posted on this Forum.
•We do NOT recommend that Anyone Buy or Sell any Securities Posted Herewith.
Any Trade entered into Risks the Possibility of Losing the Funds Invested.
•There are NO Guarantees when Buying or Selling Any Security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |